(NASDAQ: IRD) Opus Genetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.99%.
Opus Genetics's earnings in 2026 is -$106,932,000.On average, 18 Wall Street analysts forecast IRD's earnings for 2026 to be -$81,208,329, with the lowest IRD earnings forecast at -$101,304,888, and the highest IRD earnings forecast at -$17,093,063. On average, 17 Wall Street analysts forecast IRD's earnings for 2027 to be -$55,821,061, with the lowest IRD earnings forecast at -$86,149,038, and the highest IRD earnings forecast at -$35,895,433.
In 2028, IRD is forecast to generate -$49,472,209 in earnings, with the lowest earnings forecast at -$74,981,571 and the highest earnings forecast at -$17,093,063.